Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-6213
- Development stage
- Phase 2
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HRS-6213 is a chemically synthesized, investigational radio-imaging agent developed for the diagnosis of **solid tumors** using PET (positron emission tomography) imaging. It is being studied for its ability to provide high-quality images to detect and evaluate tumor presence, extent, and possibly guide treatment decisions. The drug is administered intravenously and is currently undergoing Phase 1/2 clinical trials to evaluate its safety, radiation dosimetry, pharmacokinetics, and diagnostic performance in both healthy volunteers and patients with solid tumors. The agent is being developed by Jiangsu Hengrui Medicine and its related entities[1][2][3][5][6][9].
- Brand names
- HRS-6213HRS6213HRS 6213
- Other names
- HRS-6213HRS6213HRS 6213
Beyond the preview
Go deeper on HRS-6213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-6213.